# Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

> **NCT05056337** · PHASE3 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 220 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib 4 MG Oral Capsule [Lenvima]
- **DRUG:** Toripalimab
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT05056337
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056337, "Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05056337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*